Scheper, Julian
Hildebrand, Laura S. http://orcid.org/0000-0002-1522-9591
Faulhaber, Eva-Maria
Deloch, Lisa http://orcid.org/0000-0002-5577-2302
Gaipl, Udo S. http://orcid.org/0000-0001-6375-5476
Symank, Julia
Fietkau, Rainer
Distel, Luitpold V. http://orcid.org/0000-0002-8040-3226
Hecht, Markus http://orcid.org/0000-0003-2082-216X
Jost, Tina http://orcid.org/0000-0001-8767-3774
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (02NUK050E, 02NUK017G, 02NUK050E)
Universitätsklinikum Erlangen
Article History
Received: 29 June 2022
Accepted: 15 September 2022
First Online: 13 October 2022
Declarations
:
: M. Hecht reports collaborations outside this project with Merck Serono (advisory role, speakers’ bureau, honoraria, travel expenses, research funding), MSD (advisory role, speakers’ bureau, honoraria, travel expenses, research funding), AstraZeneca (research funding), Novartis (research funding), BMS (advisory role, honoraria, speakers’ bureau), and Teva (travel expenses). U. S. Gaipl received support for presentation activities for Dr Sennewald Medizintechnik GmbH, has received support for investigator-initiated clinical studies (IITs) from MSD and AstraZeneca, and contributed at advisory boards meetings of AstraZeneca and Bristol-Myers Squibb. J. Scheper, L. S. Hildebrand, E.-M. Faulhaber, L. Deloch, J. Symank, R. Fietkau, L.V. Distel, and T. Jost declare that they have no competing interests.
: All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.